#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Sarah Sheldrick Email
Research Director . ConSynance Therapeutics
Rensselaer, NY
LocationPrimary Email
How to contact Sarah Sheldrick
Join and see Sarah's contact info for free!Current Roles
Employees:
4Revenue:
$620kAbout
ConSynance Therapeutics is a clinical-stage, biopharma company focused on rare central nervous system diseases. ConSynance’s lead candidate, CSTI-500 (aka BMS-866949), is a Phase II ready, best-in-class Triple Monoamine Reuptake Inhibitor for Prader-Willi Syndrome, a rare genetic neurodevelopmental disorder. To learn about Prader-Willi Syndrome, please visit www.FPWR.org. Our 2nd candidate, CSTI-100, is a Phase II ready, first-in-class, Melanin-Concentrating-Hormone Receptor 1 (“MCHR1â€) inhibitor for PWS as well as for Non Alcoholic Steatohepatitis (NASH).ConSynance Therapeutics Address
11 University PlaceRensselaer, NY